Harbour BioMed publishes Phase I results for TSLP antibody HBM9378 in 50 healthy adults

Reuters

Yesterday

Harbour BioMed publishes Phase I results for TSLP antibody HBM9378 in 50 healthy adults

Harbour BioMed reported online publication of first-in-human Phase I results from a randomized, double-blind, placebo-controlled single-ascending-dose trial of HBM9378 (SKB378/WIN378), a TSLP-targeting monoclonal antibody.
The study enrolled 50 healthy adults across five cohorts (20 mg to 900 mg), with eight participants receiving HBM9378 and two receiving placebo in each cohort.
Treatment-emergent adverse events were reported as comparable between HBM9378 dose groups and placebo, and no injection site reactions were observed.
Pharmacokinetic results included a median T_max range of 4.05 to 14.1 days and a mean half-life range of 55 to 65.8 days.
Anti-drug antibodies were reported in 5% (2/40) of participants who received HBM9378, with no clinical correlate or impact on drug exposure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603222314PR_NEWS_USPR_____CN16210) on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2621726337"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621726337\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621726337?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 11:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621726337","market":"us","top_or_hot":-1,"title":"Harbour BioMed publishes Phase I results for TSLP antibody HBM9378 in 50 healthy adults","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Harbour BioMed publishes Phase I results for TSLP antibody HBM9378 in 50 healthy adults\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Harbour BioMed reported online publication of first-in-human Phase I results from a randomized, double-blind, placebo-controlled single-ascending-dose trial of HBM9378 (SKB378/WIN378), a TSLP-targeting monoclonal antibody.\n        </li>\n<li>\n          The study enrolled 50 healthy adults across five cohorts (20 mg to 900 mg), with eight participants receiving HBM9378 and two receiving placebo in each cohort.\n        </li>\n<li>\n          Treatment-emergent adverse events were reported as comparable between HBM9378 dose groups and placebo, and no injection site reactions were observed.\n        </li>\n<li>\n          Pharmacokinetic results included a median T<sub>max</sub> range of 4.05 to 14.1 days and a mean half-life range of 55 to 65.8 days.\n        </li>\n<li>\n          Anti-drug antibodies were reported in 5% (2/40) of participants who received HBM9378, with no clinical correlate or impact on drug exposure.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603222314PR_NEWS_USPR_____CN16210) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harbour BioMed publishes Phase I results for TSLP antibody HBM9378 in 50 healthy adults</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarbour BioMed publishes Phase I results for TSLP antibody HBM9378 in 50 healthy adults\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-23 11:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Harbour BioMed publishes Phase I results for TSLP antibody HBM9378 in 50 healthy adults\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Harbour BioMed reported online publication of first-in-human Phase I results from a randomized, double-blind, placebo-controlled single-ascending-dose trial of HBM9378 (SKB378/WIN378), a TSLP-targeting monoclonal antibody.\n        </li>\n<li>\n          The study enrolled 50 healthy adults across five cohorts (20 mg to 900 mg), with eight participants receiving HBM9378 and two receiving placebo in each cohort.\n        </li>\n<li>\n          Treatment-emergent adverse events were reported as comparable between HBM9378 dose groups and placebo, and no injection site reactions were observed.\n        </li>\n<li>\n          Pharmacokinetic results included a median T<sub>max</sub> range of 4.05 to 14.1 days and a mean half-life range of 55 to 65.8 days.\n        </li>\n<li>\n          Anti-drug antibodies were reported in 5% (2/40) of participants who received HBM9378, with no clinical correlate or impact on drug exposure.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603222314PR_NEWS_USPR_____CN16210) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL2CC4jY:1","article_id":"2621726337","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621726337","pubTimestamp":1774235736,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Harbour BioMed reported online publication of first-in-human Phase I results from a randomized, double-blind, placebo-controlled single-ascending-dose trial of HBM9378 , a TSLP-targeting monoclonal antibody.The study enrolled 50 healthy adults across five cohorts , with eight participants receiving HBM9378 and two receiving placebo in each cohort.Treatment-emergent adverse events were reported as comparable between HBM9378 dose groups and placebo, and no injection site reactions were observed.Pharmacokinetic results included a median Tmax range of 4.05 to 14.1 days and a mean half-life range of 55 to 65.8 days.Anti-drug antibodies were reported in 5%  of participants who received HBM9378, with no clinical correlate or impact on drug exposure.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","BK1161":"生物科技","BK1583":"高瓴概念","02142":"和铂医药-B"},"translate_title":"Harbour BioMed公布TSLP抗体HBM9378在50名健康成人中的I期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":0.9},"content_text":"Harbour BioMed publishes Phase I results for TSLP antibody HBM9378 in 50 healthy adults\n    \n\n\n          Harbour BioMed reported online publication of first-in-human Phase I results from a randomized, double-blind, placebo-controlled single-ascending-dose trial of HBM9378 (SKB378/WIN378), a TSLP-targeting monoclonal antibody.\n        \n\n          The study enrolled 50 healthy adults across five cohorts (20 mg to 900 mg), with eight participants receiving HBM9378 and two receiving placebo in each cohort.\n        \n\n          Treatment-emergent adverse events were reported as comparable between HBM9378 dose groups and placebo, and no injection site reactions were observed.\n        \n\n          Pharmacokinetic results included a median Tmax range of 4.05 to 14.1 days and a mean half-life range of 55 to 65.8 days.\n        \n\n          Anti-drug antibodies were reported in 5% (2/40) of participants who received HBM9378, with no clinical correlate or impact on drug exposure.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603222314PR_NEWS_USPR_____CN16210) on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}